Table 1 Summary and characteristics of NP management guidelines included in the study
From: Clinical practice guidelines for the management of neuropathic pain: a systematic review
Guideline name | Country or region | Release time | Developed methods | Institute | Update | Clinical problem | Funding |
|---|---|---|---|---|---|---|---|
EFNS guidelines on neuropathic pain assessment | European | 2004 | Evidence-based approach | EFNS (European Federation of Neurological Societies) | 1 (2009) | assessment | EFNS |
EFNS guidelines on pharmacological treatment of neuropathic pain | European | 2006 | Evidence-based approach | EFNS | 1 (2010) | pharmacological treatment | EFNS |
EFNS guidelines on neurostimulation therapy for neuropathic pain | European | 2007 | Evidence-based approach | EFNS | 0 | neurostimulation therapy | EFNS |
EFNS guidelines on neuropathic pain assessment:revised 2009 | European | 2009 | Evidence-based approach | EFNS | 0 | assessment | EFNS |
EFNS guidelines on pharmacological treatment of neuropathic pain: 2010 revision | European | 2010 | Evidence-based approach | EFNS | 0 | pharmacological treatment | EFNS |
Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the canadian pain society | Canada | 2007 | Evidence-based approach and Consensus statement | CPS | 1 (2014) | pharmacological treatment | Pfizer Canada |
Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks | Canada | 2012 | Evidence-based approach | CPS | 0 | Interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks | CPS |
Pharmacological management of chronic neuropathic pain: Revised Consensus statement and guidelines from the canadian pain society | Canada | 2014 | Evidence-based approach and Consensus statement | CPS | pharmacological treatment | CPS | |
Pharmacologic management of neuropathic pain: Evidence-based recommendations | International | 2007 | Evidence-based approach | NeuPSIG | 0 | pharmacological treatment | IASP NeuPSIG |
NeuPSIG guidelines on neuropathic pain assessment | International | 2011 | Evidence-based approach | NeuPSIG | 0 | assessment | IASP NeuPSIG |
Interventional management of neuropathic pain: NeuPSIG recommendations | International | 2013 | Evidence-based approach | NeuPSIG | 0 | Interventional treatments | IASP NeuPSIG |
Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance | United Kindom | 2010 | Evidence-based approach | NICE | 1 (2013) | pharmacological treatment | NICE |
Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist settings | United Kindom | 2013 | Evidence-based approach | NICE | 0 | pharmacological treatment | NICE |
Clinical practice guidelines for management of neuropathic pain: Expert panel recommendations for South Africa | South Africa | 2012 | Consensus statement | painsa (Pain South Africa); NASA (Neurological Association of South Africa); PIRA (Pain Interventions and Regional Anaesthesia); SASA (South African Society of Anaesthesiologists); SASCA (South African Spinal Cord Association) | 1 (2013) | neuropathic management | Pfize |
Guidelines for the diagnosis and management of neuropathic pain: Consensus of a group of latin american experts | Latin America | 2009 | Consensus statement | FEDELAT (Latin American Federation of Chapters of the International Association for the Study of Pain) | 0 | neuropathic management | not mention |
Guidelines for the pharmacological treatment of peripheral neuropathic pain: Expert panel recommendations for the middle east region | Middle East | 2010 | Consensus statement | A multidisciplinary panel of Middle East and international experts | 0 | pharmacological treatment | Pfizer Inc |